Aisling Capital Management LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), Aisling Capital Management LP reported 13 stock positions worth $359.7 million. Its top holding was Bridgebio Pharma (BBIO) at 72.9% of the portfolio, followed by Verona Pharma (VRNA, 16.2%) and Syndax Pharmaceuticals (SNDX, 3.4%). Compared with Q1 2025, it added to 2. The biggest buy was Biomea Fusion (BMEA, shares +156%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $359.7M (Q2 2025)
- SEC Filing
- 0001766721-25-000004 ↗ filed Aug 13, 2025
Holdings Value
Holdings 13 stocks · $359.7M
| BBIO Bridgebio Pharma Inc. | 72.85% | 6,068,125 | $262.0M | No change |
| VRNA Verona Pharma Ltd. | 16.18% | 615,352 | $58.2M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 3.43% | 1,316,806 | $12.3M | Add +28.5% |
| GLUE Monte Rosa Therapeutics Inc. | 1.85% | 1,472,331 | $6.6M | No change |
| BCAX Bicara Therapeutics Inc. | 1.47% | 568,919 | $5.3M | No change |
| NUVB Nuvation Bio Inc. | 1.38% | 2,541,009 | $5.0M | No change |
| BMEA Biomea Fusion Inc. | 1.03% | 2,048,757 | $3.7M | Add +156.5% |
| CMPS Compass Pathways PLC | 0.93% | 1,198,418 | $3.4M | No change |
| ELEV Elevation Oncology Inc. | 0.29% | 2,834,910 | $1.0M | No change |
| CALC Calcimedica Inc. | 0.23% | 521,114 | $834K | No change |
| ACRS Aclaris Therapeutics Inc. | 0.17% | 434,455 | $617K | No change |
| MRKR Marker Therapeutics Inc. | 0.14% | 325,370 | $498K | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.06% | 88,607 | $212K | No change |
Portfolio Sells Q1 2025 → Q2 2025
| None this quarter. | |||
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |